|

Dual-Target Antigen-Selected CAR-NK Clinical Trials

1 actively recruiting trial

Also known as: Cyclophosphamide, EB-SELECT Dual-Target CAR-NK Cells, Fludarabine, IL-2

Pipeline

Phase 1/2: 1

Top Sponsors

  • Essen Biotech1

Indications

  • Liver Disease1
  • Colorectal Cancer (Locally Advanced or Metastatic)1
  • Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma1
  • Prostate Cancer Recurrent1
  • Melanoma (Skin Cancer)1

Other1 trial

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.